Browse by category

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

Both the new weight loss drugs and bariatric surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found. Weight loss study team: From left, Danxia Yu, PhD, Zicheng Wang, MS, Lei Wang, PhD, and Jason Samuels, MD, are co-authors of a paper evaluating body composition changes after bariatric surgery or treatment with the new w

A study led by Assistant Professor Anne Loft, Associate Professor Jesper Grud Skat Madsen and Professor Susanne Mandrup from University of Southern Denmark sheds light on what happens in the fat tissue during weight loss. All three are leading researchers at the Center of Excellence ATLAS, which investigates the molecular mechanisms driving changes in liver and fat tissues in response to obesity and weight loss. This knowledge is important because obesity-induced dysfunction

Rani Therapeutics has initiated a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. RaniPill PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen, which recently announced preclinical and clinical data, at the 2025 E

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, according to a study by University of Oxford researchers. The study shows that the average rate of weight regain is 0.4kg/month after stopping treatment, with weight and risk markers for diabetes and heart disease predicted to return to pre-treatment levels in less than two years. It also finds that

Researchers at Leipzig University and the University of Gothenburg have developed a novel approach to assessing an individual's risk of metabolic diseases such as diabetes or fatty liver disease more precisely. Instead of relying solely on the widely used body mass index (BMI), the team developed an AI-based computational model using metabolic measurements. Systems view of metabolic obesity: integrating multi-organ and multi-omics signatures. Credit: Nature Medicine (2026). D

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, according to University College London (UCL) and University of Cambridge researchers. The research led by Dr Marie Spreckley from the University of Cambridge, found a lack of robust evidence surrounding nutritional advice and support and the impact this has on

In 2025, approximately 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these

A new study co-led by the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and Prevention (ShARP) Center and the University of Hawai'i has linked certain common "forever chemicals" to a higher risk of liver disease in adolescents. Perfluoroheptanoic acid (PFHpA) These synthetic compounds, known as per- and polyfluoroalkyl substances (PFAS), may as much as triple the chances that adolescents develop a liver condition called metabolic

The FDA has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. The Wegovy pill can be used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. The pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with